Tags

Type your tag names separated by a space and hit enter

Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis.
Br J Dermatol. 2005 Jul; 153(1):203-5.BJ

Abstract

Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg(-1) day(-1) and then as an outpatient at 3 mg kg(-1) twice weekly for a further three weeks, a total of 40 mg kg(-1). Liposomal amphotericin offers a well-tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL.

Authors+Show Affiliations

Department of Infection & Tropical Medicine, Northwick Park Hospital, Harrow, UK. michael.brown@lshtm.ac.ukNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

16029352

Citation

Brown, M, et al. "Successful Liposomal Amphotericin B Treatment of Leishmania Braziliensis Cutaneous Leishmaniasis." The British Journal of Dermatology, vol. 153, no. 1, 2005, pp. 203-5.
Brown M, Noursadeghi M, Boyle J, et al. Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol. 2005;153(1):203-5.
Brown, M., Noursadeghi, M., Boyle, J., & Davidson, R. N. (2005). Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. The British Journal of Dermatology, 153(1), 203-5.
Brown M, et al. Successful Liposomal Amphotericin B Treatment of Leishmania Braziliensis Cutaneous Leishmaniasis. Br J Dermatol. 2005;153(1):203-5. PubMed PMID: 16029352.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. AU - Brown,M, AU - Noursadeghi,M, AU - Boyle,J, AU - Davidson,R N, PY - 2005/7/21/pubmed PY - 2005/10/26/medline PY - 2005/7/21/entrez SP - 203 EP - 5 JF - The British journal of dermatology JO - Br J Dermatol VL - 153 IS - 1 N2 - Existing systemic treatments for New World cutaneous leishmaniasis (CL) caused by Leishmania (vianna) braziliensis are unsatisfactory. Liposomal amphotericin B has been used extensively for the treatment of visceral leishmaniasis, but in few cases of CL, and an appropriate regimen for CL has not been described. We successfully treated a patient with multiple L. braziliensis CL lesions acquired in Belize. Liposomal amphotericin B (AmBisome) was given to our patient as an inpatient for seven daily doses of 3 mg kg(-1) day(-1) and then as an outpatient at 3 mg kg(-1) twice weekly for a further three weeks, a total of 40 mg kg(-1). Liposomal amphotericin offers a well-tolerated alternative to pentavalent antimony or amphotericin B deoxycholate for the systemic treatment of New World CL. SN - 0007-0963 UR - https://www.unboundmedicine.com/medline/citation/16029352/Successful_liposomal_amphotericin_B_treatment_of_Leishmania_braziliensis_cutaneous_leishmaniasis_ L2 - https://doi.org/10.1111/j.1365-2133.2005.06670.x DB - PRIME DP - Unbound Medicine ER -